부산대학교 도서관

Etanercept is efficacious in juvenile idiopathic arthritis (JIA) and was licensed for this indication in 2001. NICE published guidance on its use in 2002 [1]. Subsequent evidence has stimulated different prescribing patterns to those of the guidance [2–4] however commissioning may continue to rely on out-dated guidance as a measure of good practice.(Figure is included in full-text article.) AIMS: METHODS: An online survey was distributed to paediatric rheumatologists at 14 centres to establish if recent auditing (within 2 years) had been undertaken or if future audit of etanercept use against NICE guidance was planned [1]. A proposed multi-centre audit was piloted at four UK centres. RESULTS: Twenty survey responses revealed 11(58%) respondents had audited and 11 (58%) (including one who was planning to re-audit) were planning to audit current practice against NICE guidance. Responses were favourable towards a national multi-centre audit. Updating guidance on etanercept use (and other biologics) was highlighted as important. Pilot audit data for 100 cases revealed adherence to NICE guidance in 21%. See attached table. Key areas of non-compliance were:Table: Table showing summary of audit data collected in three centres. CONCLUSIONS: Pilot audit data suggests out-dated guidance is not being adhered to. Positive opinion was reported for:(Figure is included in full-text article.)